NYSE:BHVN Biohaven (BHVN) Stock Price, News & Analysis $41.19 +0.95 (+2.36%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$40.76▼$41.8450-Day Range$32.77▼$40.2152-Week Range$16.45▼$62.21Volume870,911 shsAverage Volume1.25 million shsMarket Capitalization$3.64 billionP/E RatioN/ADividend YieldN/APrice Target$55.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Biohaven alerts: Email Address Biohaven MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside33.8% Upside$55.13 Price TargetShort InterestBearish11.11% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 14 Articles This WeekInsider TradingAcquiring Shares$3.01 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($7.16) to ($6.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.93 out of 5 starsMedical Sector424th out of 936 stocksPharmaceutical Preparations Industry194th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingBiohaven has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiohaven has only been the subject of 4 research reports in the past 90 days.Read more about Biohaven's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.11% of the outstanding shares of Biohaven have been sold short.Short Interest Ratio / Days to CoverBiohaven has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Biohaven has recently decreased by 0.41%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBiohaven does not currently pay a dividend.Dividend GrowthBiohaven does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BHVN. Previous Next 2.5 News and Social Media Coverage News SentimentBiohaven has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Biohaven this week, compared to 4 articles on an average week.Search InterestOnly 9 people have searched for BHVN on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat Follows6 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biohaven insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,011,613.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders16.00% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biohaven's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biohaven are expected to grow in the coming year, from ($7.16) to ($6.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biohaven is -6.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biohaven is -6.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiohaven has a P/B Ratio of 7.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Biohaven's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Biohaven Stock (NYSE:BHVN)Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Read More BHVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BHVN Stock News HeadlinesJuly 20, 2024 | insidertrades.comBiohaven Ltd. (NYSE:BHVN) Director John W. Childs Acquires 28,400 SharesJuly 25 at 8:02 PM | msn.comMorgan Stanley starts Biohaven at overweight, cites broad pipelineJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 25 at 8:02 PM | msn.comMorgan Stanley Initiates Coverage of Biohaven (BHVN) with Overweight RecommendationJuly 24 at 8:16 AM | nl.investing.comBiohaven aandeel wint aan kracht door veelbelovende klinische studies volgens Morgan StanleyJuly 24 at 8:16 AM | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Biohaven Ltd. (BHVN), HCA Healthcare (HCA) and Kiniksa Pharmaceuticals (KNSA)July 24 at 7:10 AM | americanbankingnews.comBiohaven (NYSE:BHVN) Research Coverage Started at Morgan StanleyJuly 22, 2024 | nz.finance.yahoo.comBiohaven Ltd. (BHVN) stock historical prices & data – Yahoo FinanceJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 22, 2024 | msn.com$1M Bet On Biohaven? Check Out These 3 Stocks Insiders Are BuyingJuly 21, 2024 | americanbankingnews.comBiohaven (NYSE:BHVN) Shares Gap Up on Insider Buying ActivityJuly 20, 2024 | finance.yahoo.comBiohaven Ltd. (BHVN) Stock Price, News, Quote & History - Yahoo FinanceJuly 19, 2024 | americanbankingnews.comBiohaven Ltd. (NYSE:BHVN) Short Interest Up 6.4% in JuneJuly 19, 2024 | americanbankingnews.comDeciphera Pharmaceuticals (NASDAQ:DCPH) versus Biohaven (NYSE:BHVN) Head to Head ContrastMay 29, 2024 | markets.businessinsider.comBiohaven Reports Positive Data From Phase 1 Study Of BHV-1300May 29, 2024 | msn.comWhat's Going On With Biohaven Stock Wednesday?May 29, 2024 | msn.comBiohaven stock falls 30% premarket amid drug updatesMay 29, 2024 | prnewswire.comBiohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D DaySee More Headlines Receive BHVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)7/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:BHVN Previous SymbolNASDAQ:BHVN CUSIPN/A CIK1689813 Webwww.biohavenpharma.com Phone203-404-0410FaxN/AEmployees239Year FoundedN/APrice Target and Rating Average Stock Price Target$55.13 High Stock Price Target$60.00 Low Stock Price Target$36.00 Potential Upside/Downside+33.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($6.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-408,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-147.06% Return on Assets-113.59% Debt Debt-to-Equity RatioN/A Current Ratio4.03 Quick Ratio4.03 Sales & Book Value Annual Sales$462.51 million Price / Sales7.86 Cash FlowN/A Price / Cash FlowN/A Book Value$5.34 per share Price / Book7.71Miscellaneous Outstanding Shares88,290,000Free Float74,165,000Market Cap$3.64 billion OptionableOptionable Beta1.32 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Vladimir Coric M.D. (Age 53)Chairman & CEO Comp: $1.96MMr. Matthew Buten (Age 63)Chief Financial Officer Comp: $1.05MDr. Bruce D. Car DACVP (Age 62)Ph.D., Chief Scientific Officer Comp: $883.03kMs. Kimberly Gentile (Age 58)Senior Vice President of Clinical Operations Comp: $858.65kMs. Deb YoungDirector of Regulatory Affairs & OperationsMr. George C. Clark (Age 40)VP & Chief Accounting Officer Ms. Jennifer PorcelliVice President of Investor RelationsMr. Warren Volles J.D.General Counsel & Chief Legal OfficerMr. Clifford Bechtold M.S.President, GM of Biohaven Ireland & Chief Compliance OfficerMr. John Tilton (Age 56)Chief Commercial Officer of Rare Diseases More ExecutivesKey CompetitorsInsmedNASDAQ:INSMLegend BiotechNASDAQ:LEGNCatalentNYSE:CTLTRoivant SciencesNASDAQ:ROIVIntra-Cellular TherapiesNASDAQ:ITCIView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 74,490 shares on 7/26/2024Ownership: 0.364%Canton Hathaway LLCBought 500 shares on 7/22/2024Ownership: 0.025%John W ChildsBought 28,400 shares on 7/18/2024Total: $1.01 M ($35.67/share)ARS Investment Partners LLCBought 304,141 shares on 7/17/2024Ownership: 1.065%Oak Ridge Investments LLCBought 14,607 shares on 7/17/2024Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions BHVN Stock Analysis - Frequently Asked Questions How have BHVN shares performed this year? Biohaven's stock was trading at $42.80 at the beginning of 2024. Since then, BHVN stock has decreased by 3.8% and is now trading at $41.19. View the best growth stocks for 2024 here. How were Biohaven's earnings last quarter? Biohaven Ltd. (NYSE:BHVN) released its quarterly earnings results on Thursday, May, 9th. The company reported ($2.20) earnings per share for the quarter, missing the consensus estimate of ($1.50) by $0.70. When did Biohaven IPO? Biohaven (BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers. Who are Biohaven's major shareholders? Biohaven's top institutional shareholders include ARS Investment Partners LLC (1.07%), Bank of New York Mellon Corp (0.36%), SG Americas Securities LLC (0.03%) and Oak Ridge Investments LLC (0.02%). Insiders that own company stock include John W Childs, Vlad Coric, Gregory Bailey, Matthew Buten, George C Clark, Irina Antonijevic, Julia P Gregory, Elyse Stock, James Engelhart and Declan Doogan. View institutional ownership trends. How do I buy shares of Biohaven? Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Biohaven own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD) and QUALCOMM (QCOM). This page (NYSE:BHVN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biohaven Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biohaven With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
